Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067105 · ClinicalTrials.gov registry record · Phase 3
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 824
- Enrollment target
NCT01067105: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT01067105 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 824 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01067105, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 824 participants
- Enrollment target
Study Summary
6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.
Interventions
- DRUG ciclesonide HFA 160 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 824 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
What the finished NCT01067105 record still lists
NCT01067105 is an interventional study that assigns participants to a tested intervention. The registered 824 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which ciclesonide HFA 160 μg is the first listed.
NCT01067105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01067105 about?
NCT01067105 is a clinical study titled "A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older". 6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.
What is the current status of trial NCT01067105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 824 participants. The study started on 2010-02. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01067105?
The interventions under investigation include: ciclesonide HFA 160 μg (DRUG).
Who is sponsoring clinical trial NCT01067105?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01067105's enrollment target sits among peer trials
824 402nd of 2000 higher than 1,599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06944509 · 824 participants · NA
RADIQAL Study (Radiation Dose and Image Quality Trial)
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia